Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars
Topic
Clinical Trials
Clinical trial design, regulatory evidence requirements, innovative trial methodologies, and evidence generation strategies.
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics
Pipeline· June 13, 2026 · 15 min read
ClinicalTrials.gov competitor trial landscape: how launch teams map a crowded indication
Pipeline· June 13, 2026 · 12 min read
ClinicalTrials.gov by the numbers: 589K studies and a 58% Phase 3 results gap
Pipeline· May 22, 2026 · 13 min read
External control arm evidence for rare disease RWE packages
Pipeline· May 22, 2026 · 13 min read
Patient-reported outcome endpoint translation from trial evidence to payer evidence
By Ran Chen#Clinical Evidence#Payer Policy#AMCP Dossier